Cutting HIV medications increases public health risks significantly. Funding cuts for HIV medications can lead to millions of new infections and deaths, particularly impacting low- and middle-income countries. Maintaining funding is crucial for effective management and prevention of HIV, which remains a significant global health challenge. Antiretroviral therapy (ART) is a proven method for managing HIV infection by suppressing the viral load in patients, reducing the risk of transmission to others. ART works by targeting various stages of the HIV life cycle, ensuring that the virus does not replicate and weaken the immune system. The benefits of sustained ART funding include reduced viral loads, prevention of transmission, and improved quality of life for individuals living with HIV. For instance, programs in Sub-Saharan Africa have demonstrated substantial reductions in new HIV infections due to consistent funding for ART, showcasing its effectiveness in public health. However, challenges remain, such as drug resistance and non-adherence to treatment, which can complicate the effectiveness of ART and lead to increased health risks. Ensuring access to medications and addressing these limitations are essential for maintaining progress against HIV.